These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 37990024)

  • 1. BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
    Valanparambil RM; Lai L; Johns MA; Davis-Gardner M; Linderman SL; McPherson TO; Chang A; Akhtar A; Gamarra ELB; Matia H; McCook-Veal AA; Switchenko J; Nasti TH; Green F; Saini M; Wieland A; Pinsky BA; Solis D; Dhodapkar MV; Carlisle J; Ramalingam S; Ahmed R; Suthar MS
    NPJ Vaccines; 2023 Nov; 8(1):179. PubMed ID: 37990024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2.
    Chen WC; Hu SY; Shen CF; Chuang HY; Ker CR; Shen CJ; Cheng CM
    Vaccines (Basel); 2023 Aug; 11(9):. PubMed ID: 37766102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.
    Hyun HJ; Choi MJ; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak WS; Lee JW; Kim BG; Song JY
    Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants.
    Springer DN; Bauer M; Medits I; Camp JV; Aberle SW; Burtscher C; Höltl E; Weseslindtner L; Stiasny K; Aberle JH
    NPJ Vaccines; 2023 Aug; 8(1):110. PubMed ID: 37542025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters.
    Lasrado N; Collier AY; Miller J; Hachmann NP; Liu J; Sciacca M; Wu C; Anand T; Bondzie EA; Fisher JL; Mazurek CR; Patio RC; Powers O; Rodrigues SL; Rowe M; Surve N; Ty DM; Korber B; Barouch DH
    bioRxiv; 2023 Jan; ():. PubMed ID: 36747640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
    Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY
    Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of immune responses to mRNA booster vaccination against COVID-19.
    Arunachalam PS; Lai L; Samaha H; Feng Y; Hu M; Hui HS; Wali B; Ellis M; Davis-Gardner ME; Huerta C; Bechnak K; Bechnak S; Lee M; Litvack MB; Losada C; Grifoni A; Sette A; Zarnitsyna VI; Rouphael N; Suthar MS; Pulendran B
    J Clin Invest; 2023 May; 133(10):. PubMed ID: 36951954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    bioRxiv; 2022 Jul; ():. PubMed ID: 35898337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.
    Yau K; Kurtesi A; Qi F; Delgado-Brand M; Tursun TR; Hu Q; Dhruve M; Kandel C; Enilama O; Levin A; Jiang Y; Hardy WR; Yuen DA; Perl J; Chan CT; Leis JA; Oliver MJ; Colwill K; Gingras AC; Hladunewich MA
    Nat Commun; 2023 Sep; 14(1):6041. PubMed ID: 37758707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
    Lasrado N; Collier AY; Hachmann NP; Miller J; Rowe M; Schonberg ED; Rodrigues SL; LaPiana A; Patio RC; Anand T; Fisher J; Mazurek CR; Guan R; Wagh K; Theiler J; Korber BT; Barouch DH
    Vaccine; 2023 Nov; 41(47):6904-6909. PubMed ID: 37872011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.
    Zhu KL; Jiang XL; Zhan BD; Wang XJ; Xia X; Cao GP; Sun WK; Huang PX; Zhang JZ; Gao YL; Dai EH; Gao HX; Ma MJ
    Cell Rep; 2023 Feb; 42(2):112075. PubMed ID: 36774551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England.
    Kirsebom FCM; Harman K; Lunt RJ; Andrews N; Groves N; Abdul Aziz N; Hope R; Stowe J; Chand M; Ramsay M; Dabrera G; Kall M; Bernal JL
    Lancet Reg Health Eur; 2023 Dec; 35():100755. PubMed ID: 38115965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
    Trombetta CM; Marchi S; Leonardi M; Coppola C; Benincasa L; Marotta MG; Buonvino N; Maes P; Stufano A; Pontrelli D; Vasinioti VI; Manenti A; Camero M; Montomoli E; Decaro N; Lovreglio P
    Acta Trop; 2023 Dec; 248():107042. PubMed ID: 37863379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durability of immune responses to the booster mRNA vaccination against COVID-19.
    Arunachalam PS; Lai L; Samaha H; Feng Y; Hu M; Hui HS; Wali B; Ellis M; Huerta C; Bechnack K; Bechnack S; Lee M; Litvack M; Losada C; Grifoni A; Sette A; Zarnitsyna VI; Rouphael N; Suthar MS; Pulendran B
    medRxiv; 2022 Dec; ():. PubMed ID: 36482977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
    Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
    J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.